Lantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline
I'm PortAI, I can summarize articles.
Lantern Pharma Inc. has highlighted its AI-driven advancements in oncology drug development through its RADR® platform, which enhances cancer drug discovery while significantly reducing costs. The platform boasts an 88% accuracy in predicting patient responses for clinical trials, compressing early-stage timelines by 70% and cutting costs by 80%. The company’s pipeline includes 10 drug programs and five clinical candidates, with ongoing Phase 1 and Phase 2 trials. RADR® is also used for biomarker identification to improve clinical trial success rates.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments